Literature DB >> 7440694

Dopaminergic modulation of circadian thyrotropin rhythms and thyroid hormone levels in euthyroid subjects.

M F Scanlon, A P Weetman, M Lewis, M Pourmand, M D Rodriguez-Arnao, D R Weightman, R Hall.   

Abstract

Basal TSH levels are known to rise during the evening, but the mechanism by which this rise occurs is poorly understood. The rise in TSH in response to dopamine (DA) receptor blockade with metoclopramide in the morning in normal subjects and hypothyroid patients has provided evidence for a tonic inhibitory role for DA in the control of TSH secretion. We have tested the hypothesis in normal, euthyroid volunteers (14 females, aged 20--40 yr; 12 males, aged 22--45 yr) that the nocturnal elevation of serum TSH levels might result from a reduction in DA action on the thyrotroph, in which case a reduced TSH response to metoclopramide would be expected. We found, however, that the TSH response to DA receptor blockade with metoclopramide (10 mg, iv) was significantly greater at 2300 h than at 1100 h [net incremental response over 120 min, 14.9 +/- 2.5 vs. 6.7 +/- 1.6 mU/liter (mean +/- SE); P < 0.001], indicating greater DA inhibition of TSH release at night. Thus, the nocturnal elevation of TSH is not due to decreased DA action on the thyrotroph; rather, increased DA tone is present and may limit the TSH response to other as yet unknown factors. Thyroid hormone levels also rose significantly after metoclopramide at both 1100 and 2300 h compared with control values after placebo [incremental difference (in nanomoles per liter) between 0 and 120 min values (mean +/- SE): 1100 h, T3, 0.24 +/- 0.09 vs. -0.05 +/- 0.08 (P < 0.02); T4, 19.4 +/- 6.1 vs. -1.8 +/- 2.5 (P < 0.01); 2300 h, T3 +/- 0.53 +/-0.07 vs. 0.04 +/- 0.07 (P < 0.01); T4 20.9 +/- 5.6 vs. 2.8 +/- 3.2 (P < 0.01)]. Incremental thyroid hormone and TSH responses to metoclopramide were directly related (T3 vs. TSH, r = 0.59 and P < 0.001; T4 vs. TSH, r = 0.41 and P < 0.01), suggesting that the thyroid hormone responses were mediated by TSH and illustrating the sensitivity of the thyroid gland to even small increases in endogenous TSH levels.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7440694     DOI: 10.1210/jcem-51-6-1251

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Milk antitrypsin activity during clinical and experimental bovine mastitis.

Authors:  T Honkanen-Buzalski; T Katila; M Sandholm
Journal:  Acta Vet Scand       Date:  1981       Impact factor: 1.695

2.  Pituitary resistance to thyroid hormone action with preserved circadian rhythm of thyrotropin in a postmenopausal woman.

Authors:  N Custro; V Scafidi; A Notarbartolo
Journal:  J Endocrinol Invest       Date:  1992-02       Impact factor: 4.256

3.  Recovery of serum TSH and thyroid hormones after 3'isopropyl-3,5-diiodo-L-thyronine (DIIP) treatment: absence of inhibiting effect of bromocriptine on TSH secretion and evidence for autoregulation of serum T3 levels.

Authors:  N A Salomon-Montavon; A G Burger
Journal:  J Endocrinol Invest       Date:  1984-10       Impact factor: 4.256

Review 4.  Imbalance between thyroid hormones and the dopaminergic system might be central to the pathophysiology of restless legs syndrome: a hypothesis.

Authors:  Jose Carlos Pereira; Marcia Pradella-Hallinan; Hugo de Lins Pessoa
Journal:  Clinics (Sao Paulo)       Date:  2010-05       Impact factor: 2.365

5.  The inability of dynamic tests of prolactin and TSH secretion to differentiate between tumorous and non-tumorous hyperprolactinemia.

Authors:  R W Prescott; D G Johnston; P K Taylor; J Haigh; D R Weightman; K Hall; D B Cook
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256

6.  TRH: pathophysiologic and clinical implications.

Authors:  C R Pickardt; P C Scriba
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216

7.  Differential effects of acute DA receptor blockade with domperidone on LH and TSH release in patients with hyperprolactinemia.

Authors:  J R Peters; M D Rodriguez-Arnao; S M Foord; C Edwards; C Dieguez; S Woodhead; R Hall; M F Scanlon
Journal:  J Endocrinol Invest       Date:  1985-04       Impact factor: 4.256

8.  Association between thyroid function and disease severity in restless legs syndrome.

Authors:  Chaofan Geng; Zhenzhen Yang; Xiumei Kong; Pengfei Xu; Hongju Zhang
Journal:  Front Neurol       Date:  2022-08-12       Impact factor: 4.086

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.